Serum arylesterase and paraoxonase activities in patients with ovarian tumors

Taiwanese Journal of Obstetrics and Gynecology

Volumn 53, Issue 4, 2014, Pages 490-493

  Michalak, Slawomir ^a,b   Szubert, Sebastian ^a   Moszynski, Rafal ^a   Sajdak, Stefan ^a   Szpurek, Dariusz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Arylesterase; Ovarian cancer; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CARBOXYLESTERASE; PON1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; SPECTROPHOTOMETRY; TUMOR VOLUME; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED; OVARY DISEASE; OVARY TUMOR;

ADENOCARCINOMA; ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN DISEASES; OVARIAN NEOPLASMS; SPECTROPHOTOMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84916203259     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2013.08.009     Document Type: Article

References (20)

1. National Cancer Institute. Surveillance epidemiology and end results, SEER stat fact sheets: ovary. Available at: [accessed 31.10.14]. http://seer.cancer.gov/statfacts/html/ovary.html.
2. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1005-L1028.
3. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med 2010, 49:1603-1616.
4. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991, 19:100-106.
5. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. JClin Invest 1995, 96:2882-2891.
6. Michalak S., Kazmierski R., Hellmann A., Wysocka E., Kocialkowska-Adamczewska D., Wencel-Warot A., et al. Serum paraoxonase/arylesterase activity affects outcome in ischemic stroke patients. Cerebrovasc Dis 2011, 32:124-132.
7. Elkiran E.T., Mar N., Aygen B., Gursu F., Karaoglu A., Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007, 7:48.
8. Kafadar A.M., Ergen A., Zeybek U., Agachan B., Kuday C., Isbir T. Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochem Funct 2006, 24:455-460.
9. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998, 18:1617-1624.
10. Nagano T. Bioimaging probes for reactive oxygen species and reactive nitrogen species. JClin Biochem Nutr 2009, 45:111-124.
11. Olinski R., Zastawny T., Budzbon J., Skokowski J., Zegarski W., Dizaroglu M. DNA base modifications in chromatin of human cancerous tissues. FEBS Lett 1992, 309:193-198.
12. Conner E.M., Grisham M.B. Inflammation, free radicals, and antioxidants. Nutrition 1996, 12:274-277.
13. Hlavata L., Aguilaniu H., Pichova A., Nystrom T. The oncogenic RAS2(val19) mutation locks respiration, independently of PKA, in a mode prone to generate ROS. EMBO J 2003, 22:3337-3345.
14. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002, 9:1031-1044.
15. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. JPharm Sci 2007, 96:2181-2196.
16. Senthil K., Aranganathan S., Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 2004, 339:27-32.
17. Delimaris I., Faviou E., Antonakos G., Stathopoulou E., Zachari A., Dionyssiou-Asteriou A., et al. Serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 2007, 40:1129-1134.
18. Camuzcuoglu H., Arioz D.T., Toy H., Kurt S., Celik H., Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009, 112:481-485.
19. Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., et al. Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:2070-2077.
20. Arioz D.T., Camuzcuoglu H., Toy H., Kurt S., Celik H., Erel O. Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur J Gynaecol Oncol 2009, 30:679-682.